Cell Biology

Total Page:16

File Type:pdf, Size:1020Kb

Cell Biology Committee 2 Cell Biology Chairman C.H FRY (U.K) Members A.J KANAI (USA), A. ROOSEN (Germany), M. TAKEDA (Japan), D.N WOOD (U.K) 113 ABBREVIATIONS AND NOMENCLATURE α,β ABMA -methylene ATP NiCl2 nickel chloride ACE angiotesin converting enzyme NIH National Institutes of Health ACh acetylcholine NK receptor neurokinin receptor α-, β-actin isoforms of actin NMDA n-methyl-D-aspartate AITC allyl-isothiocyanate NO nitric oxide AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole- NOS nitric oxide synthase propionate nNOS neuronal nitric oxide synthase 3-APMPA 3-aminopropyl(methyl)phosphinic acid OAB overactive bladder 3-APPA 3-aminopropylphosphinic acid P pressure A—receptor adenosine- receptor P2-receptor receptors to ATP, subtype X/Y α -receptor alpha adrenoreceptor pA2 negative logarithm of dissociation constant AT angiotensin PACAP pituitary adenylate cyclase activating peptide ATP adenosine triphosphate 4-PBA 4-phenylbutyrate BOO bladder outlet obstruction PDE phosphdiesterase B-receptor bradykinin receptor PE phenylephrine β-receptor beta adrenoreceptor PG prostaglandin + BKCa large conductance K channel PKA protein kinase-A BSMC bladder-derived smooth muscle cell PLC phospholipase-C C bladder compliance PT pressure threshold Ca2+ calcium ion RAR recto-anal reflex CA trans-cinnamaldehyde ROK/ROCK rho-associated kinase cAMP cyclic adenosine monophosphate RT-PCR reverse transcriptase polymerase chain reaction CaM kinase Ca-mitogen kinase S1 first sacral spinal level cGK cGMP-dependent protein kinase SCI spinal cord injury cGMP cyclic guanosine monophosphate SCT spinal cord transection (transected) CICR Ca2+-induced Ca2+ release SERCA sarcoplasmic reticulum Ca2+-pump c-kit (kit)a protein-tyrosine kinase receptor sGC soluble guanylate cyclase Cl- chloride ion SHR spontaneous hypertensive rat CNS central nervous system SIS small intestine submucosa CO carbon monoxide slo-gene encoding the BK channel α-subunit + Cx gap junction protein, connexin SKCa small conductance K channel CPI-17 an MLCP inhibitor SM smooth muscle myosin DAG diacylglycerol SMPP-1M a smooth muscle myosin phosphatase 4-DAMP N-2-chloroethyl-4-piperidinyl diphenylacetate SUI stress urinary incontinence E elastic (Young’s) modulus T wall tension EAG ether-à-go-go-related gene T10 tenth thoracic spinal level ENaC epithelial Na+ channel 7TM receptor 7-transmembrane helix receptor eNOS endothelial nitric oxide synthase TMB-8 an IP receptor blocker 3 + EP receptor prostaglandin E2 (PGE2) receptor TREK channel TWIK-related K channel ER endoplasmic reticulum TRPA transient receptor potential, ankyrin ET endothelin TRPM transient receptor potential, melastatin G-protein guanosine phosphate binding protein TRPML transient receptor potential, mucolipin GABA γ-amino butyric acid TRPP transient receptor potential, polycystin G-I tract gastrointestinal tract TRPV transient receptor potential, vanilloid GRK G-protein coupled receptor kinase TTFA thenoyltrifluoroacetone HA-1077 a rho-kinase inhibitor TTX tetrodotoxin HERG human ether-a-go-go related gene TUNEL terminal deoxynucleotidyl transferase biotin- 5-HT 5-hydroxytryptamine dUTP nick end labeling ICC interstitial cell of Cajal TX thromboxane IC-MY ICC in longitudinal muscle layer UP uroplakin IC-SM ICC in circular muscle layer UPEC uropathogenic Escherichia coli iNOS inducible nitric oxide synthase UPR unfolded protein response IL-6 interleukin-6 UTP uridine triphosphate IMI inter-micturition interval VEGF vascular endothelial growth factor IP3 inositol trisphosphate VIP vasoactive intestinal peptide IPSS international prostate symptom score Y-27632 a rho-kinase inhibitor k stiffness K+ potassium ion Throughout SI (Systeme Internationale) units have been used, in particular + KATP intracellular ATP-gated K channel based on units of length, metre (m); mass, kilogramme (kg); time, second KCl potassium chloride (s); electric current, ampere (A); amount of substance (mol, M): prefixes KCNQ voltage-gated K+ channel, KQT-like superfamily are k (103), m (10-3), µ (10-6), n (10-9). Derived units are combinations 2 -3 -1 L0 optimal resting length for a muscle of SI units and include those for: voltage (V, = kg m s A ); resistance L2 second lumbar spinal level (Ω = V.A-1); conductance (S = Ω-1); force (Newton, N = kg.m.s-2); LUT lower urinary tract frequency (Hz, s-1). Some non-SI units, derived from SI units include m receptor muscarinic receptor (gene level) gram (g), minute (min), hour (hr). Some non-SI units without a precise M receptor muscarinic receptor (protein level) definition are used on occasion: these include litre (l, approximating to 3 mGluR metabotropic glutamate receptor dm ) and cm.H2O as a unit of pressure. The molar unit of concentration MLCK myosin light chain kinase (moles per dm3 solvent) is used throughout and is donated by the letter MLCP myosin light chain phosphatase M. Thus the non-standard form of concentration mol/L is avoided, as it MPEP 6-methyl-2-(phenylethynyl)pyridine has no meaning in the SI system of units. mRNA messenger ribose nucleic acid Symbols for ions in solution, eg Ca2+, Na+, etc, refer to the species that MS mechanosensitive are presumed to take part in chemical reactions. No assumptions are made mtNOS mitochondrial nitric oxide synthase about the activity coefficient of the species in solution. Symbols for Na+ sodium ion metals, Ca, Na, etc, refer to chemical moieties and this makes no statement NA noradrenaline as to the sub-fraction that will take part in a biological process, eg Na- NANC non-adrenergic, non-cholinergic pump. 114 CONTENTS I. INTRODUCTION VI. BIOMECHANICAL PROPERTIES OF THE BLADDER WALL II. THE UROTHELIUM AND 1. ACTIVE AND PASSIVE CONTRACTILE SUBUROTHELIUM PROPERTIES OF THE BLADDER WALL 2. COMPLIANT PROPERTIES OF THE 1. INTRODUCTION BLADDER AND BLADDER WALL 2. THE UROTHELIUM: CHANGES IN DISEASE 3. BIOMECHANICAL PROPERTIES OF AND BACTERIAL INFECTIONS LOWER URINARY TRACT TISSUES AND 3. SECRETORY AND SIGNALING COLLAGEN SUBTYPES PROPERTIES OF THE UROTHELIUM/ 4. PROPERTIES OF THE PELVIC FLOOR AND SUBUROTHELIUM GENUINE STRESS INCONTINENCE 4. INTERACTIONS BETWEEN 5. THE ACTIVE PROPERTIES OF MUSCLE IN UROTHELIUM/ SUBUROTHELIUM AND THE LOWER URINARY TRACT DETRUSOR 6. TENSION AND PRESSURE III. CELL PHYSIOLOGY OF MUSCLE VII. THE LOWER CONTRACTION: DETRUSOR GASTRO-INTESTINAL TRACT 1. THE NORMAL PHYSIOLOGY OF THE 1. CONTRACTILE MECHANISMS RECTUM AND ANUS 2. ELECTRICAL ACTIVITY AND ION 2. INNERVATION CHANNELS 3. SMOOTH MUSCLE TISSUES 3. DETRUSOR ACTIVATION AND 4. INTERSTITIAL CELLS RELAXATION 5. FUTURE DIRECTIONS 4. SPONTANEOUS ACTIVITY 5. TRIGONE VIII. NOVEL MOLECULAR TARGETS IV. THE URETHRA 1. INTRODUCTION 2. METABOTROPIC RECEPTORS 1. INTRODUCTION 3. ION-CHANNELS 2. URETHRAL SMOOTH MUSCLE IX. TISSUE REPLACEMENT AND 3. URETHRAL SKELETAL MUSCLE TRANSLATIONAL RESEARCH V. CELL PHYSIOLOGY OF 1. INTRODUCTION NEUROACTIVE AGENTS IN THE 2. INJECTABLE THERAPY LOWER URINARY TRACT 3. TISSUE REPLACEMENT 1. MUSCARINIC CHOLINERGIC 4. APPROACHES TO GRAFT GENERATION TRANSMISSION 5. CONCLUSION 2. ADRENERGIC TRANSMISSION X. RECOMMENDATIONS FOR LOWER 3. PURINERGIC TRANSMISSION URINARY TRACT AND LOWER 4. NITRERGIC MECHANISMS GASTRO-INTESTINAL TRACT 5. NICOTINE AND NICOTINIC RECEPTORS RESEARCH 6. ADENOSINE RECEPTORS 7. NEUROPEPTIDES REFERENCES 115 Cell Biology C.H FRY, A.J KANAI, A. ROOSEN, M. TAKEDA, D.N. WOOD be applied to the G-I tract. Equally, our understanding I. INTRODUCTION of the mode of action of some useful drugs and a greater understanding of their molecular targets has This aim of this report is to describe the cell and tissue been radically altered, which should enable the physiology and biochemistry of the lower urinary tract development of better-targeted drugs. Figure 1 shows that will help to understand the pathophysiology of a diagrammatic representation of the bladder wall the overactive bladder and lower gastrointestinal (G- with some of the structures and receptors that will be I) tract and to highlight potential avenues whereby described in the following sections. the conditions may be better managed. The report Increased understanding of these tissues has also will attempt to explain the most important features of facilitated tissue-engineering approaches to develop the lower urinary and G-I tracts, and describe important functional implants and recent advances will be changes that are associated with functional disorders. described. This report has attempted to reflect these It is not always possible to differentiate between advances. It will refer to the previous report when primary and secondary changes to tissue that are basic principles were described, and when some associated with tract dysfunction but this is not aspects were discussed in depth and re-examination necessarily important if potentially useful targeted might be repetitious. All referenced material is from models are identified that may be used to develop peer-reviewed publications, most of which have new therapeutic and other approaches to manage appeared after the previous consultation [1]. urinary and faecal incontinence. Since the previous consultation [1] there has been II. THE UROTHELIUM AND considerable advance in our understanding of the SUBUROTHELIUM lower urinary and G-I tract, particularly with respect to the bladder. In particular the urothelium has emerged 1. INTRODUCTION as an important tissue in mediating lower urinary tract sensations, and the principles learnt may in the future The previous report [1] concentrated on the structure Figure 1: Schematic representation of the bladder wall and its
Recommended publications
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome
    Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2012, Article ID 486067, 11 pages doi:10.1155/2012/486067 Review Article Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome Emanuele Sinagra, Claudia Romano, and Mario Cottone Division of Internal Medicine “Villa Sofia-V. Cervello” Hospital, University of Palermo, Via Trabucco 180, 90146 Palermo, Italy Correspondence should be addressed to Emanuele Sinagra, [email protected] Received 20 March 2012; Revised 28 May 2012; Accepted 4 July 2012 Academic Editor: Giovanni Barbara Copyright © 2012 Emanuele Sinagra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Irritable bowel syndrome (IBS) accounts for 25% of gastroenterology output practice, making it one of the most common disorders in this practice. Psychological and social factors may affect the development of this chronic disorder. Furthermore, psychiatric symptoms and psychiatric diseases are highly prevalent in this condition, but the approach to treating these is not always straightforward. As emphasized in the biopsychosocial model of IBS, with regard to the modulatory role of stress-related brain-gut interactions and association of the disease with psychological factors and emotional state, it proves useful to encourage psychopharmacological treatments and psychosocial therapies, both aiming at reducing stress perception. The aim of this paper is to analyze the effectiveness of psychopharmacological treatment and psychological interventions on irritable bowel syndrome. 1. Introduction In fact, IBS has a multifactorial etiology, involving altered gut reactivity and motility, altered pain perception, and Irritable bowel syndrome (IBS) is a chronic, relapsing, and alteration of the brain-gut axis [8].
    [Show full text]
  • Pharmacological Treatment of Urinary Incontinence
    Committee 8 Pharmacological Treatment of Urinary Incontinence Chairman KARL-ERIK ANDERSSON (USA) Co-Chairman C. R CHAPPLE (U.K) Members L. CARDOZO (U.K), F. C RUZ (Portugal), H. HASHIM (U.K), M.C. MICHEL (The Netherlands), C. TANNENBAUM (Canada), A.J. WEIN (USA) 631 CONTENTS A. INTRODUCTION X. OTHER DRUGS I. PUBLICATION SEARCHES XI. COMBINATIONS II. CENTRAL NERVOUS CONTROL XII. FUTURE POSSIBILITIES III.PERIPHERALNERVOUS CONTROL C.DRUGS USED FOR IV. PATHOGENESIS OF BLADDER TREATMENT OF STRESS CONTROL DISORDERS URINARY INCONTINENCE V. BLADDER CONTRACTION I. α-ADRENCEPTOR AGONISTS VI. MUSCARINIC RECEPTORS II. β-ADRENOCEPTOR ANTAGONISTS B. DRUGS USED FOR TREATMENT OF OVERACTIVE III. β-ADRENOCEPTOR AGONISTS BLADDER SYMPTOMS/ DETRUSOR OVERACTIVITY IV. SEROTONIN-NORADRENALINE UPTAKE INHIBITORS I. ANTIMUSCARINIC (ANTICHOLINERGIC) DRUGS D.DRUGS USED FOR II. DRUGS ACTING ON MEMBRANE TREATMENT OF CHANNELS OVERFLOW INCONTINENCE III. DRUGS WITH “MIXED” ACTION E. HORMONALTREATMENT OF URINARY INCONTINENCE IV. α-ADRENOCEPTOR (AR) ANTAGONISTS I. ESTROGENS V. β-ADRENOCEPTOR AGONISTS II. OTHER STEROID HORMONE VI. PHOSPHODIESTERASE (PDE) RECEPTOR LIGANDS INHIBITORS III. DESMOPRESSIN VII. ANTIDEPRESSANTS VIII. CYCLOOXYGENASE (COX) INHIBITORS F. CONSIDERATIONS IN THE ELDERLY IX. TOXINS REFERENCES 632 Pharmacological Treatment of Urinary Incontinence KARL-ERIK ANDERSSON C. R CHAPPLE, L. CARDOZO, F. CRUZ, H. HASHIM, M.C. MICHEL, C. TANNENBAUM, A.J. WEIN Table 1. ICI assessments 2008: Oxford guidelines (modified) A. INTRODUCTION Levels of evidence Level 1: Systematic reviews, meta-analyses, good The function of the lower urinary tract (LUT) is to store quality randomized controlled clinical trials and periodically release urine, and is dependent on (RCTs) the activity of smooth and striated muscles in the Level 2: RCTs , good quality prospective cohort bladder, urethra, and pelvic floor.
    [Show full text]
  • DITROPAN XL (Oxybutynin Chloride)
    ® DITROPAN XL (oxybutynin chloride) Extended Release Tablets DESCRIPTION ® DITROPAN XL (oxybutynin chloride) is an antispasmodic, anticholinergic agent. Each DITROPAN XL® Extended Release Tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers. Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C22H31NO3•HCl. Its structural formula is: Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis. DITROPAN XL® also contains the following inert ingredients: cellulose acetate, hypromellose, lactose, magnesium stearate, polyethylene glycol, polyethylene oxide, synthetic iron oxides, titanium dioxide, polysorbate 80, sodium chloride, and butylated hydroxytoluene. System Components and Performance DITROPAN XL® uses osmotic pressure to deliver oxybutynin chloride at a controlled rate over approximately 24 hours. The system, which resembles a conventional tablet in appearance, comprises an osmotically active bilayer core surrounded by a semipermeable membrane. The bilayer core is composed of a drug layer containing the drug and excipients, and a push layer containing osmotically active components. There is a precision-laser drilled orifice in the semipermeable membrane on the drug-layer side of the tablet. In an aqueous environment, such as the gastrointestinal tract, water permeates through the membrane into the tablet core, causing 1 Reference ID: 3059075 the drug to go into suspension and the push layer to expand. This expansion pushes the suspended drug out through the orifice.
    [Show full text]
  • Hyoscyamine Sulfate Odtorally Dispersible Tabletsrx Only
    HYOSCYAMINE SULFATE ODT- hyoscyamine sulfate tablet, orally disintegrating Acella Pharmaceuticals, LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Hyoscyamine Sulfate ODT Orally Dispersible Tablets Rx Only DESCRIPTION Each round, green, peppermint flavored, orally dispersible tablet contains: Hyoscyamine Sulfate, USP …… 0.125 mg. Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. Inactive ingredients include: Green LKB #LB-620, lactose monohydrate, magnesium stearate (veg), mannitol USP, peppermint flavor, starch and stearic acid. CLINICAL PHARMACOLOGY Hyoscyamine has actions similar to those of atropine, but is more potent in both its central and peripheral effects. This product inhibits gastrointestinal propulsive motility and decreases gastric acid secretions. This product controls excessive pharyngeal, tracheal, and bronchial secretion. This product is absorbed totally and completely by sublingual administration as well as oral administration. Once absorbed, this product disappears rapidly from the blood and is distributed throughout the entire body. The majority of hyoscyamine sulfate is excreted in the urine unchanged within the first 12 hours and only traces of hyoscyamine sulfate are found in the breast milk. INDICATIONS AND USAGE This product may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries and diverticulitis. It can also be used to control gastric secretion, visceral spasm and hypermotility in cystitis, pylorospasm and associated abdominal cramps. Along with appropriate analgesics, this product is indicated in symptomatic relief of biliary and renal colic and as a drying agent in the relief of symptoms of acute rhinitis.
    [Show full text]
  • Urinary Antispasmodics TCO 02.2018
    Therapeutic Class Overview Urinary antispasmodics INTRODUCTION • Overactive bladder (OAB) is defined as urinary urgency, with or without urge incontinence, usually with frequency and nocturia. Urinary incontinence has been shown to greatly reduce quality of life in areas such as mental and general health in addition to physical and social functioning (American Urological Association 2019, Coyne et al 2008, International Continence Society 2015). • Behavioral therapies (eg, bladder training, bladder control strategies, pelvic floor muscle training and fluid management) are considered first-line treatment in all patients with OAB (American Urological Association 2019). • Urinary antispasmodics are used as first-line pharmacological therapy in OAB (American Urological Association 2019, American College of Obstetricians and Gynecologists 2015, Blok et al 2019, Burkhard et al 2018). • The urinary antispasmodics used for the treatment of OAB belong to 2 classes of drugs, which include anticholinergic compounds known as muscarinic receptor antagonists, and the beta-3 adrenergic agonist, mirabegron. The anticholinergic agents act as antagonists of acetylcholine at muscarinic cholinergic receptors, thereby relaxing smooth muscle in the bladder and decreasing bladder contractions. Both immediate-release (IR) and extended-release (ER) formulations (LA, XL, and XR) are available for oxybutynin (Ditropan), tolterodine (Detrol), and trospium. Darifenacin (Enablex) and fesoterodine (Toviaz) are also supplied as ER tablets. Oxybutynin is also formulated
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Trospium Chloride: an Update on a Quaternary Anticholinergic for Treatment of Urge Urinary Incontinence
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central REVIEW Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence David RP Guay Abstract: Trospium chloride is a quaternary ammonium compound, which is a competitive antagonist at muscarinic cholinergic receptors. Preclinical studies using porcine and human Department of Experimental and Clinical Pharmacology, College of detrusor muscle strips demonstrated that trospium chloride was many-fold more potent than Pharmacy, University of Minnesota, oxybutynin and tolterodine in inhibiting contractile responses to carbachol and electrical Minneapolis, MN, USA stimulation. The drug is poorly bioavailable orally (< 10%) and food reduces absorption by 70%– 80%. It is predominantly eliminated renally as unchanged compound. Trospium chloride, dosed 20 mg twice daily, is significantly superior to placebo in improving cystometric parameters, reducing urinary frequency, reducing incontinence episodes, and increasing urine volume per micturition. In active-controlled trials, trospium chloride was at least equivalent to immediate-release formulations of oxybutynin and tolterodine in efficacy and tolerability. The most problematic adverse effects of trospium chloride are the anticholinergic effects of dry mouth and constipation. Comparative efficacy/tolerability data with long-acting formulations of oxybutynin and tolterodine as well as other anticholinergics such as solifenacin and darifenacin are not available. On the basis of available data, trospium chloride does not appear to be a substantial advance upon existing anticholinergics in the management of urge urinary incontinence. Keywords: urge incontinence, trospium, anticholinergic, overactive bladder Introduction Urge urinary incontinence (UUI), the most frequent type of urinary incontinence (UI), has as typical symptoms incontinence associated with urinary frequency (> 8 micturitions/day) and urgency (sudden, strong desire to urinate).
    [Show full text]
  • Drugs Used to Manage Urinary Incontinence in Dogs & Cats
    PLUMB’S THERAPEUTICS BRIEF h Rx SOLUTIONS h PEER REVIEWED ChronicDrugs UpperUsed to Respiratory Manage UrinaryTract Disease Incontinence in a Cat in Dogs & Cats Margie Scherk, DVM, DABVP (Feline) catsiNK Julie KathleenVancouver, Byron, BC, DVM, Canada MS, DACVIM The Ohio State University REDLIGHT GREEN LIGHT h PEER REVIEWED Urinary incontinence is a common presenting complaint primar- Following are therapeutic targets for the various causes of ily affecting dogs and occasionally cats. The most common incontinence. cause of urinary incontinence is urethral sphincter mechanism incompetence (USMI), which typically affects spayed female DRUGS TO MANAGE STORAGE DISORDERS dogs and occasionally male dogs. Other causes include disor- a-Adrenergic Drug ders such as urine retention and bladder outflow obstruction, Phenylpropanolamine which are more common in male dogs. Phenylpropanolamine is a nonselective a-agonist that also has some β-agonist effects. It indirectly increases urethral smooth Therapeutic objectives include treating signs of incontinence- muscle tone and may also induce relaxation of the detrusor mus- related disorders such as storage disorders (eg, USMI, ectopic cle via β-adrenergic effects. Its nonselectivity may lead to stimu- ureter, overactive bladder) and emptying disorders (eg, lation of vasoconstriction and overall sympathetic activation. detrusor-urethral dyssynergia, functional obstruction, ure- throspasm, detrusor atony, neurogenic upper motor neuron Formulation → Oral bladder). Goals for treating storage disorders include increas- ing urethral sphincter smooth and striated muscle tone, Dose (dogs, cats) → 1-2 mg/kg PO q8-12h1 increasing bladder compliance, and decreasing intravesicular pressures during filling and storage. Goals for treating empty- Key Points ing disorders include decreasing urethral sphincter smooth h Dose escalation or increased frequency over time may be and striated muscle tone, increasing detrusor contraction, and necessary.
    [Show full text]
  • HYOSCYAMINE SULFATE ORALLY DISINTEGRATING TABLETS 0.125 MG Rx Only
    HYOSCYAMINE SULFATE- hyoscyamine sulfate tablet, orally disintegrating Avera McKennan Hospital Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- HYOSCYAMINE SULFATE ORALLY DISINTEGRATING TABLETS 0.125 MG Rx Only. DESCRIPTION Hyoscyamine Sulfate Orally Disintegrating Tablets, 0.125 mg are white, round, flat beveled edge tablets debossed "634" on one side. Scored on other side. Hyoscyamine Sulfate Orally Disintegrating Tablets contain 0.125 mg hyoscyamine sulfate formulated for oral administration. Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The molecular formula is (C17H23NO3)2•H2SO4•2H2O and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl- 8-azabicyclo [3.2.1] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structural formula: Each tablet also contains as inactive ingredients: mannitol, croscarmellose sodium and magnesium stearate. CLINICAL PHARMACOLOGY Hyoscyamine sulfate inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, and the exocrine glands. At therapeutic doses, it is completely devoid of any action on autonomic ganglia. Hyoscyamine sulfate inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Hyoscyamine sulfate also controls excessive pharyngeal, tracheal and bronchial secretions. Hyoscyamine sulfate is absorbed totally and completely by sublingual administration as well as oral administration.
    [Show full text]
  • Therapeutic Class Review Urinary Antispasmodics
    Therapeutic Class Review Urinary Antispasmodics Therapeutic Class · Overview/Summary: The urinary antispasmodics are Food and Drug Administration (FDA)-approved for the treatment of overactive bladder (OAB) and include darifenacin (Enablex®), fesoterodine (Toviaz®), oxybutynin (Ditropan®) solifenacin (Vesicare®), tolterodine (Detrol®) and trospium (Sanctura®). Extended-release (ER, LA, XL and XR) formulations are available for oxybutynin (Ditropan XL®), tolterodine (Detrol LA®) and trospium (Sanctura XL®). Oxybutynin is also available as a topical gel (Gelnique®) and transdermal patch (Oxytrol®).1-12 The International Continence Society defines OAB as urinary urgency, with or without urge incontinence, usually with frequency and nocturia.13 Urinary incontinence has been shown to greatly reduce quality of life in areas such as mental and general health in addition to physical and social functioning.14 These agents act as antagonists of acetylcholine at muscarinic cholinergic receptors, thereby relaxing smooth muscle in the bladder and decreasing bladder contractions.1-12 The urinary antispasmodics have a similar safety and efficacy profile and primary differ in their receptor selectivity and tolerability profiles. The M2 and M3 muscarinic receptor subtypes are highly concentrated in the bladder and are responsible for detrusor contraction, while M1, M4 and M5 are located throughout the body. Solifenacin and darifenacin are believed to be “uroselective” for the M3 receptor in the bladder; however, the clinical implications of this suggestion have not been established.15 Because of the various muscarinic receptor subtypes and locations in organs throughout the body, these agents are associated with various adverse events including blurred vision, dry mouth, constipation and urinary retention. Central nervous system adverse events such as dizziness, somnolence, and headaches may also occur.1-12 The development of ER formulations with more predictable pharmacokinetics has led to a lower incidence of anticholinergic adverse events.
    [Show full text]